Search results for "Prostatic neoplasm"

showing 10 items of 285 documents

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines

2018

Neutrophil gelatinase-associated lipocalin (NGAL a.k.a lipocalin 2, lnc2) is a secreted protein which can form a complex with matrix metalloproteinase-9 (MMP9). This MMP9/NGAL complex has been associated with metastasis. MMP9 and NGAL are detected in the urine of patients afflicted with many different types of cancer, including prostate cancer. The effects of p53, NF-κB and the androgen receptor (AR) on the expression of NGAL was examined in four prostate cancer cell lines. Prostate cancer cell lines that are AR negative and expressed either mutant or no p53 (DU145 and PC3) displayed higher levels of NGAL expression compared to the prostate cancer cell lines (LNCaP and 22Rv-1) which are AR …

Male0301 basic medicinep53Cancer ResearchLipocalinMMP9Metastasis03 medical and health sciencesProstate cancerDU145GeneticCell Line Tumorandrogen receptorLNCaPGeneticsmedicineHumansNF-kappaBNGALMolecular BiologyChemistryNF-kappa BProstatic Neoplasmsmedicine.diseaseprostate cancerGene Expression Regulation NeoplasticAndrogen receptor030104 developmental biologyMatrix Metalloproteinase 9Receptors AndrogenCell cultureCancer researchMolecular MedicineTumor Suppressor Protein p53
researchProduct

Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.

2014

Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface of several leukocytes and tissue cells and has a key function in detecting pathogen and danger-associated molecular patterns. The role of TLR4 in the pathophysiology of several age-related diseases is also well recognized, such as prostate cancer (PCa). TLR4 polymorphisms have been related to PCa risk, but the relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic reviews. Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide association studies analyzing this relationship and included only white populatio…

MaleProstate cancer polymorphisms of TLR4 aggressive prostate cancer risk meta-analysisSystematic Reviewslcsh:MedicineGenome-wide association studySingle-nucleotide polymorphismBiologyResearch and Analysis MethodsBioinformaticsPolymorphism Single NucleotideProstate cancerGenotypeGeneticsCancer GeneticsmedicineHumansSettore MED/05 - Patologia ClinicaGenetic Predisposition to DiseaseStatistical Methodslcsh:ScienceGenotypingGenetic associationEvolutionary BiologyMultidisciplinarylcsh:RProstatic NeoplasmsBiology and Life SciencesResearch Assessmentmedicine.diseaseImmunity InnateToll-Like Receptor 4Systematic reviewMeta-analysisPhysical SciencesGenetic Polymorphismlcsh:QPopulation GeneticsMathematicsStatistics (Mathematics)Genome-Wide Association StudyResearch ArticleMeta-AnalysisPLoS ONE
researchProduct

Oxidative burst inhibitory and cytotoxic amides and lignans from the stem bark of Fagara heitzii (Rutaceae)

2009

Two amides, heitziamide A and heitziamide B and two phenylethanoids, heitziethanoid A and heitziethanoid B together with thirteen known compounds were isolated from F. heitzii (Letouzey). The structures of all compounds were established by spectroscopic analysis. Nine compounds were evaluated for oxidative burst inhibitory activity in a chemoluminescence assay and for cytotoxicity against PC-3 prostate cancer cells. All compounds exhibited a clear suppressive effect on phagocytosis response upon activation with serum opsonized zymosan at the range of IC50 = 2.0-6.5 mu M, but no cytotoxic effect was observed (IC50 > 100 mu M). (C) 2009 Elsevier Ltd. All rights reserved.

MaleCytotoxicityChemical structurePhagocytosisPlant ScienceHorticultureHeterocyclic Compounds 2-RingBiochemistryAntioxidantsLignansInhibitory Concentration 50chemistry.chemical_compoundPhagocytosisCell Line TumorHumansImmunologic FactorsCytotoxic T cellFagara heitziiCytotoxicityRutaceaeMolecular BiologyRespiratory BurstLignanPlant StemsPlant ExtractsZymosanZymosanProstatic NeoplasmsBiological activityGeneral MedicineAntineoplastic Agents PhytogenicAmidesOxidative burstinhibitionRespiratory burstchemistryBiochemistryPlant BarkPhenylethanoidsPhytochemistry
researchProduct

Regulation of cell-to-cell communication in non-tumorigenic and malignant human prostate epithelial cells.

2002

BACKGROUND Gap-junction-mediated intercellular communication (GJIC) is required for normal development and tissue homeostasis. However, the role of GJIC in human prostate carcinogenesis and progression remains ill-defined. METHODS The ability of hormones, anti-hormones, and the anti-hypertensive drug, forskolin, to restore GJIC in non-tumorigenic (RWPE-1 and PWR-1E) and malignant (RWPE-2, LNCaP, DU-145) human prostate epithelial cell lines, was examined by Scrape-Loading/Dye Transfer (SL/DT) and Fluorescence Recovery After Photobleaching (FRAP) methods using an Ultima laser cytometer. RESULTS Results from both assays show that PWR-1E, RWPE-2, LNCaP, and DU-145 cells have weak or absent GJIC…

Malemedicine.medical_specialtyEstroneUrologyCell CommunicationBiologyurologic and male genital diseasesmedicine.disease_causeConnexinschemistry.chemical_compoundProstate cancerCell–cell interactionInternal medicineLNCaPmedicineTumor Cells CulturedHumansTissue homeostasisForskolinColforsinGap JunctionsProstatic NeoplasmsEpithelial Cellsmedicine.diseaseEndocrinologyCell Transformation NeoplasticOncologychemistryCell cultureCancer researchCarcinogenesisImmortalised cell lineThe Prostate
researchProduct

Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?

2015

Objective Knowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study. Methods Newly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inc…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentlcsh:MedicineAntineoplastic AgentsBreast NeoplasmsBreast cancerInternal medicinemedicineHumansPrecision Medicinelcsh:ScienceLife StyleSocioeconomic statusAgedChemotherapyMultidisciplinarybusiness.industryPalliative Carelcsh:RProstatic NeoplasmsCancerMiddle Agedmedicine.diseaseCombined Modality TherapyPhysical therapySmoking cessationMarital statusFemaleSmoking Cessationlcsh:QColorectal NeoplasmsbusinessBody mass indexResearch ArticlePLOS ONE
researchProduct

Extraprostatic Spindle Cell Stromal Tumor of the Prostate: Case Report

2007

Several benign and malignant nonepithelial and stromal-like lesions arise in the prostate. Because such lesions are rare, their recognition is essential, because treatment and prognosis depend on an adequate pathohistologic classification. We report a case of an 83-year-old man with a stromal tumor of the prostate of uncertain malignant potential (STUMP). He presented with urinary retention and rectal constipation. On bimanual examination, a rectally and suprapubically palpable mass was found. Imaging studies revealed a 12 x 8 cm pararectal inhomogeneous mass of uncertain origin compressing rectum and urethra. The tumor was resected by a retropubic approach and examined immunohistochemicall…

Aged 80 and overMalePathologymedicine.medical_specialtyConstipationUrinary retentionbusiness.industryUrologyCarcinomaCellProstatic NeoplasmsRectumExtraprostaticUrethramedicine.anatomical_structureProstateAbdominal NeoplasmsmedicineHumansmedicine.symptomStromal tumorbusinessUrology
researchProduct

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

2016

<b><i>Purpose:</i></b> The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. <b><i>Methods:</i></b> Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m<sup>2</sup> every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously. The…

OncologyMalemedicine.medical_specialtyCancer Research030232 urology & nephrologyProstate neoplasmAntineoplastic AgentsDocetaxelCastration resistantAdenocarcinomaTaxaneSingle CenterAntineoplastic Agent03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineTaxoidmedicineClinical endpointHumansProspective StudiesAgedResponse rate (survey)GynecologyCabazitaxelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMetastatic castration-resistant prostate cancerProspective StudieProstatic Neoplasms Castration-ResistantDocetaxelOncologyCabazitaxel030220 oncology & carcinogenesisChemotherapy regimenDisease ProgressionPrednisoneTaxoidsbusinessmedicine.drugHuman
researchProduct

Fluorinated and pegylated polyaspartamide derivatives to increase solubility and efficacy of Flutamide

2012

New fluorinated amphiphilic copolymers based on a biocompatible polyaspartamide have been prepared in order to obtain polymeric micelles useful for delivering anticancer drugs. In particular, α,β-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) has been derivatized with polyethylene glycol (PEG(2000)) and ethylendiamine (EDA). Both these portions form the hydrophilic part of the copolymer, while the hydrophobic moiety is given by 1,2,4-oxadiazoles: 5-pentafluorophenyl-3-perfluoroheptyl-1,2,4-oxadiazole (PPOX) or 3-carboxyethyl-5-pentadecafluoroheptyl-1,2,4-oxadiazole (CPOX). Copolymers named PHEA-PEG(2000)-EDA-PPOX and PHEA-PEG(2000)-EDA-CPOX have been prepared with various degrees of derivati…

MaleAntineoplastic Agents HormonalPolymersSize-exclusion chromatographyPharmaceutical SciencePolyethylene glycolAdenocarcinomaPolyethylene Glycolschemistry.chemical_compoundDrug Delivery SystemsCell Line TumorPolymer chemistryCopolymerHumansSolubilityDerivatizationMicellesCell Proliferationchemistry.chemical_classificationDrug CarriersOxadiazolesProstatic NeoplasmsDihydrotestosteroneSettore CHIM/06 - Chimica OrganicaPolymerEthylenediaminesFlutamideCancer targeting cell model colloidal particles drug delivery polymerSolubilitychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryChromatography GelMicroscopy Electron ScanningPyrenePeptidesHydrophobic and Hydrophilic InteractionsJournal of Drug Targeting
researchProduct

A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification

2018

IMPORTANCE: Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI–transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. OBJECTIVE: To determine whether an MRI-based prediction model can reduce unnecessary biopsies in patients with suspected prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Patients underwent MRI, MRI-TRUS fusion-guided biopsy, and 12-core systematic biopsy in 1 session. The development cohort used to derive the prediction model consisted of 400 patients from 1 institution enrolled between …

Image-Guided BiopsyMaleCancer Researchmedicine.medical_specialtyProstate biopsy030232 urology & nephrologyRisk Assessment03 medical and health sciencesProstate cancer0302 clinical medicineProstateBiopsymedicineHumansAgedUltrasonographyOriginal Investigationmedicine.diagnostic_testReceiver operating characteristicbusiness.industryProstateProstatic NeoplasmsMagnetic resonance imagingMiddle AgedPrognosismedicine.diseaseCombined Modality TherapyMagnetic Resonance ImagingTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisCohortRadiologybusinessImage-Guided BiopsyBiomarkers
researchProduct

Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update

2018

Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities. In addition, further survival prolongation by changing treatment paradigm in both metastasized hormone-sensitive and nonmetastatic castration-resistant disease …

MaleOncologymedicine.medical_specialtyCombination therapyCost effectivenessUrologyAntineoplastic AgentsDiseaselaw.invention03 medical and health sciencesProstate cancerchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineBone Density Conservation Agentsbusiness.industryAbiraterone acetateProstatic NeoplasmsBone metastasismedicine.diseaseZoledronic acidOncologychemistry030220 oncology & carcinogenesisDrug Therapy Combinationbusinessmedicine.drugUrologic Oncology: Seminars and Original Investigations
researchProduct